Spots Global Cancer Trial Database for camrelizumab
Every month we try and update this database with for camrelizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma | NCT04724226 | Hepatocellular ... | Camrelizumab; A... | 18 Years - 70 Years | Sun Yat-sen University | |
| Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma | NCT04440917 | Head and Neck S... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | NCT04884906 | Locally Advance... | Camrelizumab radiotherapy Albumin Paclita... Cisplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer | NCT04390945 | Esophageal Canc... | Camrelizumab | 18 Years - 75 Years | The First Affiliated Hospital of Henan University of Science and Technology | |
| Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | NCT06326736 | Pancreatic Canc... | Surgery Camrelizumab SJ-Neo006 Gemcitabine+Abr... | 18 Years - 75 Years | Jinling Hospital, China | |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | NCT06231680 | Lung Cancer, No... Esophageal Carc... | Camrelizumab Thalidomide 50m... Thalidomide 100... Thalidomide 200... Chemotherapy | 18 Years - | Henan Cancer Hospital | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | NCT04346381 | Solid Tumor | Camrelizumab Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer | NCT04201990 | Lung Cancer | Camrelizumab an... | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | NCT05225844 | Gastrointestina... Immunotherapy Targeted Therap... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Harbin Medical University | |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC | NCT06288360 | Cervical Cancer Locally Advance... PD-L1 Negative Neoadjuvant Che... | Camrelizumab Paclitaxel-albu... Cisplatin radical surgery | 18 Years - 70 Years | Tongji Hospital | |
| Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | NCT05193292 | Colorectal Neop... Intestinal Neop... | Camrelizumab Trastuzumab XELOX regimen mFOLFOX6 regime... FOLFIRI regimen mXELIRI regimen mIRIS regimen | 18 Years - | Fudan University | |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | NCT05049681 | Esophageal Canc... | Camrelizumab Apatinib | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04548271 | Nasopharyngeal ... | Camrelizumab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas | NCT05142865 | Advanced or Met... | Camrelizumab Etoposide Carboplatin Cisplatin Apatinib | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | NCT04639180 | Hepatocellular ... | Camrelizumab Rivoceranib (Ap... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer | NCT06215677 | Colon Cancer Mismatch Repair... Immunotherapy | Camrelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | NCT04067986 | Colorectal Canc... | Camrelizumab Apatinib | 18 Years - 75 Years | Zhongshan Hospital Xiamen University | |
| Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | NCT04337606 | Non Hodgkin Lym... | Chidamide Decitabine Camrelizumab | 18 Years - 65 Years | Chinese PLA General Hospital | |
| Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | NCT05198609 | Hepatocellular ... | FOLFOX-HAIC Camrelizumab Apatinib | 18 Years - | Sun Yat-sen University | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT06121557 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Chemotherapeuti... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Camrelizumab Combined With Local Treatment in NSCLC Patients With BM | NCT04291092 | NSCLC Stage IV Brain Metastase... Immunotherapy | Immunotherapy WBRT Chemotherapy | 18 Years - | Zhejiang Cancer Hospital | |
| Camrelizumab Utilization on Patients With Advanced Liver Cancer | NCT04487704 | Advanced Hepato... | camrelizumab | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | |
| Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | NCT04612894 | Thyroid Cancer | Camrelizumab an... surgery core needle bio... | 14 Years - | Fudan University | |
| Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | NCT05011227 | Recurrent Nasop... | Camrelizumab Chemotherapy endoscopic surg... | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | NCT05476380 | Esophageal Carc... | camrelizumab | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma | NCT05637268 | Esophagus Cance... | Camrelizumab Paclitaxel Cisplatin | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation | NCT05761470 | Her-2 Negative ... HRR Gene Mutati... | Camrelizumab Fluzoparib Nab-paclitaxel | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer | NCT04539600 | Hypopharyngeal ... Immunotherapy Induction Chemo... | Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | NCT04676997 | Triple Negative... | Camrelizumab Nab paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS | NCT03997747 | Osteosarcoma | cytology specim... | 12 Years - | Peking University People's Hospital | |
| Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | NCT04195828 | Advanced Gastri... | Camrelizumab Apatinib Mesyla... nab-paclitaxel S1 | 18 Years - 75 Years | Fujian Medical University | |
| Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | NCT04479527 | Hepatocellular ... | Camrelizumab | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | NCT04642664 | Biliary Tract C... Cholangiocarcin... Biomarker Hepatobiliary N... | Apatinib plus C... | 18 Years - | Peking Union Medical College Hospital | |
| Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | NCT04910126 | Soft Tissue Sar... Neoplasms, Conn... Sarcoma Metasta... Sarcoma,Soft Ti... | Camrelizumab Adriamycin | 18 Years - 60 Years | Wuhan Union Hospital, China | |
| Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | NCT05189483 | Soft Tissue Sar... | Albumin-Bound P... Camrelizumab | 16 Years - 70 Years | Henan Cancer Hospital | |
| Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | NCT06289062 | Cervical Cancer Neoadjuvant Che... Fertility Prese... | Camrelizumab Cisplatin Nab paclitaxel biopsy | 18 Years - 45 Years | Tongji Hospital | |
| A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | NCT05042375 | Non-small Cell ... | camrelizumab + ... pembrolizumab camrelizumab | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients | NCT05825443 | Immunotherapy Chemotherapy | Camrelizumab | 18 Years - 80 Years | Nanfang Hospital, Southern Medical University | |
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab | NCT03919539 | Drug Resistance... Biomarkers for ... | 5hmc testing | 12 Years - | Peking University People's Hospital | |
| A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC | NCT04286958 | Esophageal Canc... | Camrelizumab | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | NCT05447702 | Triple Negative... | Camrelizumab Apatinib Nab-paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 75 Years | West China Hospital | |
| MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | NCT04074564 | Sarcoma | MASCT-I, Camrel... | 14 Years - 70 Years | HRYZ Biotech Co. | |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | NCT05924997 | Advanced Hepato... | adebrelimab, ca... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | NCT05322499 | Stage IV Esopha... | Camrelizumab Irinotecan Paclitaxel Paclitaxel-albu... Docetaxel Anlotinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | NCT04850040 | Hepatocellular ... | Apatinib Mesyla... Camrelizumab Oxaliplatin | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | NCT05624099 | Esophageal Neop... Esophageal Dise... Digestive Syste... | camrelizumab Paclitaxel drug... Platinum drug Radiation | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma | NCT04365049 | PDAC - Pancreat... | Radiotherapy Nab-paclitaxel Gemcitabine Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | NCT04907344 | Triple Negative... | Camrelizumab Nab-Paclitaxel Carboplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma | NCT04143984 | Nasopharyngeal ... | Induction chemo... Carbon-ion radi... Camrelizumab | 18 Years - 70 Years | Shanghai Proton and Heavy Ion Center | |
| Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma | NCT05798793 | Oral Squamous C... | Camrelizumab pl... TP | 18 Years - 70 Years | Hospital of Stomatology, Wuhan University | |
| Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | NCT05475678 | Breast Cancer Triple Negative... Camrelizumab | （Carrelizumab +... TCb regimen | 18 Years - 70 Years | Henan Cancer Hospital | |
| A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer | NCT04512417 | Esophageal Canc... | Camrelizumab+Ra... Camrelizumab | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | NCT05095636 | Gastric Cancer Metastasis | Apatinib Mesyla... Camrelizumab | 18 Years - 75 Years | Fudan University | |
| Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | NCT05664139 | Malignant Melan... Liver Metastase... | Recombinant Hum... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma | NCT04888429 | Sarcomatoid Car... | Camrelizumab Famitinib | 18 Years - 75 Years | Tongji Hospital | |
| A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | NCT05151549 | Cervical Cancer | Camrelizumab Cisplatin or Ca... | 18 Years - | Hunan Cancer Hospital | |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | NCT06333561 | Hepatocellular ... Lenvatinib PD-1 Inhibitor Hepatic Arteria... | Hepatic arteria... Lenvatinib Tislelizumab Toripalimab Sintilimab Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL | NCT05093140 | Primary Extrano... DLBCL | Camrelizumab | 18 Years - 65 Years | Sun Yat-sen University | |
| A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer | NCT05183958 | Esophageal Canc... | Radiotherapy gr... Camrelizumab Chemotherapy | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL) | NCT04070040 | Primary Central... | Camrelizumab | 18 Years - | Beijing Sanbo Brain Hospital | |
| Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | NCT05789043 | Acral Melanoma | camrelizumab+ap... camrelizumab+ap... camrelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | NCT04156698 | Hypopharyngeal ... Immunotherapy Chemotherapy | Docetaxel Cisplatin Capecitabine Camrelizumab | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | NCT05011227 | Recurrent Nasop... | Camrelizumab Chemotherapy endoscopic surg... | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | NCT04506138 | Esophageal Squa... | Camrelizumab Paclitaxel for ... Carboplatin | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | NCT04318730 | Adrenocortical ... | Camrelizumab | 18 Years - | West China Hospital | |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | NCT05367687 | Adjuvant Therap... | Camrelizumab、Ri... Camrelizumab | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT04861467 | HNSCC | Camrelizumab | 18 Years - 70 Years | ChineseAMS | |
| Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer | NCT05547737 | NSCLC | Camrelizumab | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC | NCT04167774 | Non-Small Cell ... | Camrelizumab nb-Paclitaxel | 18 Years - | Sun Yat-sen University | |
| The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma | NCT04415385 | Pancreatic Canc... | Camrelizumab Apatinib | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer | NCT04152889 | Gastric Cancer ... | Camrelizumab S-1 Docetaxel | 18 Years - 80 Years | RenJi Hospital | |
| A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer | NCT04152889 | Gastric Cancer ... | Camrelizumab S-1 Docetaxel | 18 Years - 80 Years | RenJi Hospital | |
| A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer | NCT04616040 | Esophageal Canc... | Camrelizumab | 18 Years - | Peking University | |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | NCT04768075 | Non-Small-Cell ... | Camrelizumab Placebo Cisplatin Carboplatin Pemetrexed Paclitaxel Albumin paclita... | 18 Years - 75 Years | Guangdong Association of Clinical Trials |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
